VALN (VALN) Stock Price & Analysis

VALN (VALN) fell 0.47% to USD 5.31 as of June 10, 2026 at 05:28 UTC, according to Nexqual real-time market data.

VALN last closed at USD 5.34; the session ranged USD 5.26–5.5 on volume of 14,745 shares. Market capitalization is $503.51M, with a 52-week range of USD 5.06–12.25 (NMS). Source: Nexqual, June 10, 2026 at 05:28 UTC.

Key Statistics (as of June 10, 2026 at 05:28 UTC)

PriceUSD 5.31
Change▼ 0.47% (down)
Previous CloseUSD 5.34
OpenUSD 5.47
Day RangeUSD 5.26 – 5.5
52-Week RangeUSD 5.06 – 12.25
Volume14,745 shares
Market Cap$503.51M
ExchangeNMS

Technical Analysis (VALN)

Nexqual's technical model rates VALN "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:28 UTC.

Overall SignalSELL
RSI (14)37.25 (neutral)
vs SMA50Below (USD 5.83)
MACD-0.13 (negative)

Analyst Ratings (VALN)

Wall Street analysts rate VALN "None" based on 4 analysts, with a mean price target of USD 12.2 (range USD 4.8–18), per Nexqual as of June 10, 2026 at 05:28 UTC.

Consensus RatingNone
Analyst Count4
Mean TargetUSD 12.2
High TargetUSD 18
Low TargetUSD 4.8
Buy / Hold / Sell3 / 0 / 1

Earnings (VALN)

Next Earnings Date2026-03-18
EPS EstimateUSD -0.08
Revenue Estimate$37.72M

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD -0.42 vs est -0.21 ▼ miss
2025-09-30USD -0.6 vs est -0.26 ▼ miss
2025-06-30USD -0.16 vs est -0.19 ▲ beat

Source: Nexqual, June 10, 2026 at 05:28 UTC.

Financials & Fundamentals (VALN)

Total Revenue$156.33M
Revenue Growth (YoY)-37.20%
Gross Margin-25.27%
Operating Margin-76.67%
Profit Margin-88.30%
ROE-109.57%
Debt / Equity273.15
Current Ratio2.14
Total Cash$105.27M
Total Debt$209.50M
Free Cash Flow$-31.01M

Source: Nexqual, June 10, 2026 at 05:28 UTC.

Financial Health Score (VALN)

Nexqual rates VALN's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:28 UTC.

GrowthMixed — Revenue +3.0% YoY (annual), slow
ProfitabilityCritical — Gross margin -25%, operating -77%
Balance SheetWeak — $105M cash vs $210M debt
Cash FlowWeak — FCF negative: -$31M, burning cash
EfficiencyCritical — ROE -110%, ROA -14.5%

Ownership (VALN)

Insider Ownership+0.00%
Institutional Ownership+3.62%
Shares Outstanding94.82M
Float73.69M
Short % of Float+0.19%

Source: Nexqual, June 10, 2026 at 05:28 UTC.

Leadership (VALN)

VALN is led by Thomas Lingelbach (age 62), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:28 UTC.

President, CEO & DirectorThomas Lingelbach (age 62)
Chief Financial OfficerPeter Buhler (age 54)
Chief Operating OfficerVincent Dequenne (age 58)
Chief Scientific OfficerHanneke Schuitemaker (age 60)
Vice President of Investor RelationsJoshua Drumm

Major Backers & Investors (VALN)

Notable institutional backers of VALN include Frazier Life Sciences Management, L.P. , Novo Holdings A/S, General American Investors Company Inc, according to Nexqual as of June 10, 2026 at 05:28 UTC.

Active Investors

InvestorStake
Frazier Life Sciences Management, L.P. 2.42%
Novo Holdings A/S1.11%
General American Investors Company Inc0.74%

Source: Nexqual, June 10, 2026 at 05:28 UTC.

Peers & Related Stocks

SymbolNamePriceChange
MOLNMolecular Partners AGUSD 3.88▼ 5.37%
PHVSPharvaris N.V.USD 31.6▲ 1.64%
IPHAInnate Pharma S.A.USD 1.77▲ 3.51%
TYRATyra Biosciences, Inc.USD 25.94▼ 2.63%
DSGNDesign Therapeutics, Inc.USD 10.55▼ 0.94%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:28 UTC. This page is informational and not investment advice.